Sourabh Agrawal

In recent years, the private hospital sector in India has seen significant growth, drawing nearly 50% of FDI in the country’s healthcare ecosystem. Alongside the pharmaceutical industry, hospitals have become a prime focus for investors. Major PE investments, such as those involving Manipal, Max, and the Aster DM-Quality Care merger, are set to expand bed capacities and push hospital networks into non-urban areas. Additionally, the rise in health insurance, with players like LIC of India entering the fray, further boosts healthcare spending. These trends will significantly increase hospital expenditure on medicines and consumables, presenting immense opportunities for India’s top pharmaceutical companies. Corporate hospitals are adopting advanced analytical tools for drug procurement and prioritizing quality and service in their partnerships. This shift underscores the need for Indian pharma companies to rethink their approach. Developing a robust Key Account Management (KAM) strategy is essential. This involves building sustainable client relationships, transitioning from transactional to strategic account management, and leveraging data analytics to align with account priorities. As the healthcare sector evolves, Indian pharma companies must adapt to these changes to remain competitive and capitalize on emerging opportunities.

44

3 Comments

𝗦𝘂𝗿𝗮𝗷'𝘀 𝗠𝗶𝘀𝘁𝗮𝗸𝗲: 𝗔 𝗖𝗮𝘂𝘁𝗶𝗼𝗻𝗮𝗿𝘆 𝗧𝗮𝗹𝗲 𝗳𝗼𝗿 𝗔𝗺𝗯𝗶𝘁𝗶𝗼𝘂𝘀 𝗟𝗲𝗮𝗱𝗲𝗿𝘀 Suraj, a rising star in pharma sales, found himself at the helm of a mid-tier company with an ambitious goal: double revenue in one year. Eager to prove his worth, he charged ahead, setting aggressive targets for his regional teams without taking the time to understand their challenges or build their confidence. The results were disastrous. Morale plummeted, employees left in droves, and the company faced a crisis. Suraj's pursuit of personal glory had blinded him to the needs of his team and the realities of the market. This scenario mirrors the ancient tale of Milo of Croton, the legendary wrestler who built his strength by lifting a growing calf each day. Milo's gradual approach allowed him to achieve incredible feats, but it also offers a valuable lesson for modern leaders: 𝘀𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗹𝗲 𝗴𝗿𝗼𝘄𝘁𝗵 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝘀 𝗽𝗮𝘁𝗶𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗮 𝗳𝗼𝗰𝘂𝘀 𝗼𝗻 𝗯𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝗮 𝘀𝘁𝗿𝗼𝗻𝗴 𝗳𝗼𝘂𝗻𝗱𝗮𝘁𝗶𝗼𝗻. 𝗞𝗲𝘆 𝗧𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀 𝗳𝗼𝗿 𝗟𝗲𝗮𝗱𝗲𝗿𝘀 𝗦𝘁𝗮𝗿𝘁 𝗦𝗹𝗼𝘄: Just as Milo didn't start by lifting a full-grown bull, leaders should avoid setting unrealistic expectations from the outset. Begin with achievable goals that build momentum and confidence. 𝗣𝗿𝗲𝗽𝗮𝗿𝗲 𝗬𝗼𝘂𝗿 𝗧𝗲𝗮𝗺: Suraj's mistake was failing to invest in his team's development. Leaders must equip their employees with the skills, resources, and support they need to succeed. This includes clear communication, ongoing training, and opportunities for growth. 𝗚𝗿𝗮𝗱𝘂𝗮𝗹 𝗜𝗻𝗰𝗿𝗲𝗮𝘀𝗲: Milo's success came from incrementally increasing the weight he lifted. Similarly, leaders should gradually raise expectations as their team's capabilities grow. This prevents burnout and fosters a culture of continuous improvement. 𝗔𝗽𝗽𝗹𝘆𝗶𝗻𝗴 𝗧𝗵𝗲𝘀𝗲 𝗟𝗲𝘀𝘀𝗼𝗻𝘀 Whether you're leading a sales team, managing a project, or pursuing personal goals, remember the story of Milo. Sustainable success comes from a steady, patient approach that prioritizes building a strong foundation and investing in the development of your team. 𝗪𝗵𝗮𝘁 𝗮𝗿𝗲 𝘆𝗼𝘂𝗿 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀 𝗳𝗿𝗼𝗺 𝘁𝗵𝗶𝘀 𝘀𝘁𝗼𝗿𝘆? 𝗛𝗼𝘄 𝗰𝗮𝗻 𝘆𝗼𝘂 𝗮𝗽𝗽𝗹𝘆 𝘁𝗵𝗲𝘀𝗲 𝗹𝗲𝘀𝘀𝗼𝗻𝘀 𝘁𝗼 𝘆𝗼𝘂𝗿 𝗽𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹 𝗮𝗻𝗱 𝗽𝗲𝗿𝘀𝗼𝗻𝗮𝗹 𝗹𝗶𝗳𝗲? #leadership #coaching #growth

11

What pricing strategy could be this , skimming, prohibitory or value based. Whatever...but belies the logic and not sustainable.Whooping 72,00,000 INR or USD 90,000 per patient per year. #pricing #access

21

2 Comments

The Pomodoro Technique is a time management method developed by Francesco Cirillo in the late 1980s. It encourages breaking work into intervals, traditionally 25 minutes long, separated by short breaks. Here’s a quick overview of how the technique works: 1. Choose a task you want to focus on. 2. Set a timer for 25 minutes (a "Pomodoro"). 3. Work on the task until the timer rings. 4. Take a short break (5 minutes is recommended). 5. After four Pomodoros, take a longer break (15-30 minutes). This technique is great for improving focus and productivity by creating a sense of urgency and regular rest. It can also help reduce burnout from long, uninterrupted work sessions.

8

3 Comments

Thoughts on this? >> Honasa Consumer Share Price Hits Upper Circuit On Reports Of Co-Founder Varun Alagh Raising Stake >> Comment below! >>> lqventures.com #industry40 #IoT #mhealth #AI #healthtech

1

Postoperative wound infections, also known as surgical site infections (SSIs), are complications that can occur after surgery, leading to delayed healing, increased morbidity, and extended hospital stays. Effective management involves a combination of preventive measures, prompt diagnosis, and appropriate treatment strategies. Management of Postoperative Wound Infections: 1. Prevention: • Preoperative Measures: Advise patients to shower or bathe using soap the day before or on the day of surgery. Consider nasal decolonization with mupirocin and chlorhexidine body wash for procedures where Staphylococcus aureus is a likely cause of infection. • Intraoperative Measures: Maintain sterile techniques, minimize tissue handling, and ensure proper ventilation in the operating room. Use appropriate antiseptic skin preparations and avoid unnecessary hair removal. • Postoperative Measures: Monitor the surgical site for signs of infection, maintain proper wound care, and educate patients on recognizing symptoms of infection. 2. Diagnosis: • Clinical Examination: Assess for signs such as redness, swelling, warmth, pain, and purulent discharge at the surgical site. Systemic signs may include fever and elevated white blood cell count. • Microbiological Testing: Obtain wound cultures to identify the causative organisms and determine their antibiotic sensitivities. 3. Treatment: • Antibiotic Therapy: Initiate empirical antibiotic therapy based on the most likely pathogens and local resistance patterns, then adjust according to culture results. • Wound Care: Implement appropriate wound care techniques, including debridement of necrotic tissue, drainage of abscesses, and application of suitable dressings to promote healing. • Adjunct Therapies: Consider advanced therapies such as negative pressure wound therapy (NPWT) to enhance healing in complex or chronic wounds. Unity Health Pharmaceutical Nigeria Ltd’s Approach and Solutions: Unity Health Pharmaceutical Nigeria Ltd is committed to addressing postoperative wound infections through a comprehensive approach that includes: • Provision of Quality Pharmaceuticals: Supplying a range of effective antibiotics and antiseptics tailored to treat common pathogens associated with wound infections in Nigeria. • Educational Initiatives: Offering training programs for healthcare professionals on best practices in wound care and infection prevention, ensuring adherence to international guidelines. • Research and Development: Investing in the development of advanced wound care products and therapies, including antimicrobial dressings and innovative treatment modalities, to improve patient outcomes. • Collaboration with Healthcare Facilities: Partnering with hospitals and clinics to implement standardized protocols for the prevention and management of SSIs, thereby reducing infection rates and enhancing patient care. Come join us to provide lifeline for All.

1

"Leverage your strengths". "Bridge the gaps". "Add value". As vanilla as as the above business mantras may sound, they couldn't be more accurate. With IPHEX 2024 right round the corner, Team Shah TC is all set to reaffirm our standing as your go-to-partner for exports of finished dosage forms from Asia. As we all should have known by now, the pandemic did make some pretty big dents in global pharma supply chains, directly impacting the availability of essential life-saving drugs, as much as their affordability. And if importers were truly serious about making 'supply chains more resilient', finding a distributor, or the right one at least, would have been on top of their list. So what is it that Shah TC does differently? What makes it the potentially right distributor for your FDFs? Well, firstly, we leverage our core strengths. Reputed as India's largest importer of APIs and serving more than 1000 domestic formulation companies, expansion into finished dosages was quite a natural one. It allowed us to ensure steady supply of cost competitive raw materials to our API customers, who have now also become our esteemed FDF suppliers, through sturdy contract manufacturing partnerships. Secondly, we bridge an important supply chain gap. Global FDF importers have realized that logisitics is not just to be looked at as a 2% or 3% cost to product. But much rather, an absolute art in itself. With warehouses at almost every pharma manufacturing hub of India, grouping, consolidating and simplifying logistics couldn't be an easier task for Shah TC. It's no secret. To be a good distributor, infrastructure is key and critical. Lastly, our signficant value addition comes from our 24 year expertise in ensuring the safety, quality, documentation and traceability of the raw materials used, but this time, for the manufacturing of our very own formulations. Cherry on the cake, our bargaining power to negotiate price discounts on bulk raw material imports, automatically helps reduce the cost of the product without ever having to 'cut corners' or squeeze our contract manufacturing partners. It's a win-win-win model! Don't believe me? Visit us at IPHEX and meet our fantastic Export Team! Let them tell you about our supply chain expertise and our unique business model. Book your meeting today! To our Global Customers, you may reach out to, - Priyanka Singhal (SAARC, Africa, LATAM regions) - Nikita Gupta (APAC, MENA regions) And to our Domestic Suppliers, please connect with - Divya Jain (Procurement) - Pooja Uniyal (Sourcing) Lokk forward to meeting you there! #withshahtc #pharma #export #supplychain #distribution #logisitics #manufacturing #IPHEX #India

44

3 Comments

“Ayurveda has long emphasized the importance of food combinations for optimal health. In my latest reel, I discuss how popular foods like paneer, cheese, and dahi can negatively impact health if consumed at the wrong times. Discover the Ayurvedic perspective on mindful eating and avoid common dietary pitfalls to support your well-being. #Ayurveda #HealthTips #MindfulEating #NutritionWisdom”

16

1 Comment

Today's The Times Of India published a report from The Lancet is talking about worsening patients outcome in developed countries where regularity norms are strict. Now just imagine what is going on here in India. Private hospitals are taking YoY minimum growth target at 20% come what may. Doctors are forced to generate revenue as per corporate practice and in the name of treatment. What to do? Model of BUSINESS is like that only.

7

😶 #Indian-manufactured #drugs have seen a surge in popularity among #American #patients, driven by the combination of affordability and quality. Indian export to USA is therefore increasing. In an effort at using the regulatory system to fight competition from Indian pharma companies, eight Indian pharma companies are amongst the 11 global companies that have been served with “#Form483” of United States Food and Drug Administration (USFDA) since the start of 2024. The companies are Cipla Limited (three times), Torrent Pharmaceuticals Limited (once), Dr. Reddy’s Laboratories Ltd CTO Unit 6 (once), Laurus Synthesis Pvt Ltd (once), Eugia Pharma (four times), Zydus Lifesciences Ltd (two times), Alkem Laboratories Limited and Jubilant Generics (both once). The remaining three companies are located in Japan, Iceland and China. #BigPharma is very influential in any US administration, which is why pharma prices in the US are often a hundred or more times more than equivalents produced by Indian companies and are trying to block Indian competition through FDA: https://lnkd.in/dHke7F_e

1

𝐋𝐨𝐨𝐤𝐢𝐧𝐠 𝐟𝐨𝐫 𝐚 𝐫𝐞𝐥𝐢𝐚𝐛𝐥𝐞 𝐩𝐚𝐫𝐭𝐧𝐞𝐫 𝐢𝐧 𝐭𝐡𝐞 𝐎𝐓𝐂 (𝐎𝐯𝐞𝐫-𝐓𝐡𝐞-𝐂𝐨𝐮𝐧𝐭𝐞𝐫) 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐬𝐩𝐚𝐜𝐞?  Look no further than India! With a booming industry valued at US$ 50 billion and projected for explosive growth, India offers a wealth of opportunities for your OTC brand. India has emerged as a global leader in pharmaceutical manufacturing, offering a compelling proposition for third-party partnerships. This focus on quality extends beyond just generics, with numerous manufacturers adhering to international standards like US FDA, UK MHRA, TGA, and EU GMP. Partnering with Indian manufacturers allows you to tap into a vast network supplying over 180 countries, giving your OTC product global reach. India's pharmaceutical industry, as discussed, offers a wealth of opportunities for global partnerships. Here’s how we at Nutriva can help you navigate this advantage. 𝐄𝐱𝐭𝐞𝐧𝐬𝐢𝐯𝐞 𝐍𝐞𝐭𝐰𝐨𝐫𝐤 & 𝐄𝐱𝐩𝐞𝐫𝐭𝐢𝐬𝐞: We connect you with a vast network of pre-vetted, reliable manufacturers and suppliers across all pharmaceutical segments. This saves you time and effort in finding qualified partners. 𝐏𝐫𝐞-𝐪𝐮𝐚𝐥𝐢𝐟𝐢𝐞𝐝 𝐯𝐞𝐧𝐝𝐨𝐫𝐬: Nutriva has undertaken and successfully brought more than 1000 brands to the market since its inception in 2013. Over time, we have collected data, which you can now leverage to save time and resources, ensuring you partner with the ideal candidate for your needs. 𝐍𝐞𝐭𝐰𝐨𝐫𝐤: Nutriva's network of over 10,000 healthcare professionals provides you with unparalleled access to real-time market intelligence. Gain a comprehensive understanding of the global landscape and make informed decisions that propel you ahead of the curve. Visit https://nutrivaglobal.com/ to learn more about how we can help you leverage India's vast potential and achieve your business goals. #OTCManufacturingIndia #Pharmaceuticals #MakeinIndia #GlobalOTCPartner #Nutraceuticals #GrowYourOTCBrand #InternationalPharmaReach #PharmaSuppliers #MarketResearchForOTC #NutrivaYourOTCSuccess #NutrivaGlobal

38

2 Comments

Below article on socioeconomic changes are also affecting India's generic pharma market. Right time forTransformation. *GTM (Go-to-Market) to GTP (Go-to-Patient) Approach:* 1. Direct-to-Patient (DTP) marketing: Engage patients through digital channels, patient support programs, and educational content. 2. Patient advocacy: Partner with patient organizations, focus groups, and influencers. 3. Digital health platforms: Leverage telemedicine, health apps, and online consultation platforms. *Sustainable Business Models:* 1. Value-based healthcare: Focus on outcomes, patient satisfaction, and cost-effective solutions. 2. Data-driven decision-making: Utilize analytics, AI, and machine learning for insights. 3. Patient-centric services: Offer personalized medicine, adherence programs, and disease management. *Innovative Sales Strategies:* 1. Key Account Management (KAM): Build relationships with healthcare providers, hospitals, and retailers. 2. Multichannel engagement: Combine digital, face-to-face, and tele-detailing interactions. 3. Medical liaison: Provide scientific expertise, education, and support. *Differentiation in a Generic Market:* 1. Branded generics: Develop unique brand identities, packaging, and marketing. 2. Quality differentiation: Highlight manufacturing excellence, quality control, and regulatory compliance. 3. Service-based differentiation: Offer flexible packaging, patient support programs, and logistics excellence. *Digital Transformation:* 1. E-commerce platforms: Partner with online pharmacies, e-commerce sites, or create own platforms. 2. Digital marketing: Leverage social media, search engine optimization (SEO), and content marketing. 3. Analytics and insights: Monitor market trends, patient behavior, and sales performance. *Partnerships and Collaborations:* 1. Healthcare provider partnerships: Collaborate with hospitals, clinics, and medical institutions. 2. Patient organization partnerships: Work with patient advocacy groups, NGOs, and support networks. 3. Technology partnerships: Integrate with healthtech startups, digital health platforms, and data analytics firms. - Enhance patient engagement - Improve brand differentiation - Increase sales efficiency - Foster sustainable growth - Stay competitive in a rapidly changing market.

44

5 Comments

Hi,  We are pleased to offer a range of pioneering products for the treatment of Psoriasis, Vitiligo, as well as for skin and hair care, all based on Indian Traditional Medicines. Our offerings include proprietary research-based medicines rooted in Ayurveda and Siddha. If you would like to learn more, please do not hesitate to contact us at "[email protected]". #Psoriasis #Vitiligo #skin #hair #care #pharmaceutical #medicines #pharmaceuticalindustry #pharmaceuticals #pharmaceuticalcompanies #pharmaceuticalcompany #pharmaceuticalsciences #pharmaceuticalmarketing #pharmaceuticaltechnology #pharmaceuticalproducts #pharmaceuticalmanufacturing #pharmaceuticalsales #pharmaceutics #drugdevelopment #lifesciences #drugsupply #tablets #capsule #generics #genericdrugs #pharmaceuticals #pharmaceuticalsales #pharmaceuticalmarketing #pharmaceuticaltechnology #pharmaceuticalpackaging #pharmaceuticalmanufacturing #pharmaceuticaldevelopment #pharmaceuticalindustry #pharmaceuticalcompany #pharmaceuticalsciences #pharmaceuticalcompanies #qualitycontrol #analyticalsolutions #analyticalchemistry #analyticalscience #pharmaceutics #pharmamanufacturing 

2

India’s Role in Healthcare & Life Sciences GCCs 🌟 🌍 India: A #Global Leader in #Healthcare & Life Sciences Innovation 🧬 India is solidifying its position as a global powerhouse for Healthcare and Life Sciences Global Capability Centers (#GCCs). With 95+ GCCs, employing 280,000+ professionals, the nation is spearheading advancements in R&D, clinical trials, and healthcare technology. 📊 Key Insights: -15% of GCC talent in India is dedicated to healthcare and life sciences. -Bengaluru leads with 33% of India’s Healthcare GCCs, followed by Hyderabad (20%) and Mumbai (19%)​. -Hyderabad accounts for 35% of India's pharmaceutical production and is home to 200+ US FDA-approved sites, making it a hub for life sciences innovation. -800+ pharma and biotech companies operate in Hyderabad, valued at $50+ billion. -85% of life sciences GCCs are concentrated in Bengaluru, Hyderabad, Mumbai, and Delhi/NCR, underscoring India’s strategic advantage. 💡 Driving Forces Behind India’s Success: -Innovation & Technology: AI, ML, and data analytics are revolutionizing healthcare. GCCs contribute to drug discovery, clinical data analysis, and personalized medicine, enabling faster, cost-effective solutions. -Talent Pool: With 1.5M STEM graduates annually, India provides unmatched access to skilled professionals in life sciences, digital, and engineering. Cost Efficiency: Indian GCCs offer 40–60% cost savings compared to Western counterparts, ensuring scalability​ -Government Support: Initiatives like Make in India, Pharma City, and Genome Valley attract global leaders to invest in cutting-edge R&D​. 🌟 Global Leaders & Impact: Companies are leveraging India’s GCCs for: Accelerated drug discovery and clinical trial management. Advanced technologies such as AI-driven imaging, cloud solutions, and real-world evidence analytics. Contributions to 400+ patents and state-of-the-art innovation hubs​ 🔗 #HealthcareInnovation #LifeSciences #GlobalCapabilityCenters #India #IndianGCC #GCC #AIinHealthcare #PharmaLeadership #InnovationHub #Bengaluru #jobseeker #job #Hyderabad #DigitalHealthcare #R&DTransformation #GlobalLeadership Source: https://lnkd.in/g2uzG8rT

26

9 Comments